CIRS Group
Medical Devices
C&K Testing
Carbon Neutrality

European Union Proposed to Identify Resorcinol as SVHC

from CIRS by

1 Jun. 2021, European Union has proposed to identify resorcinol (CAS No.: 108-46-3, EC No.: 203-585-2) and submitted G/TBT/N/EU/803 notification to WTO.

France submitted to the European Chemicals Agency on 25 Feb. 2020, a dossier for the identification of resorcinol as a substance of very high concern due to its endocrine disrupting properties. However, as the Member State Committee did not reach unanimous agreement on the endocrine disrupting properties of resorcinol, this substance did not list in the SVHC List. Then the Commission notes that medical case reports provide evidence that the application of ointments containing high concentrations of resorcinol to ulcerated or to undamaged skin over long periods led to hypothyroidism in patients, which was reversible upon cessation of exposure, which provide direct information that resorcinol results in serious adverse effects in humans.

Based on the above information, resorcinol is to be identified as a substance of very high concern pursuant to Article 57, point (f), of Regulation (EC) No 1907/2006 due to its endocrine disrupting properties, with probable serious effects to human health which give rise to an equivalent level of concern to those of other substances listed in Article 57, points (a) to (e), of that Regulation. It is estimated that it will be listed into the SVHC List at the end of this year as the 26th batch.

Substance Name: Resorcinol

CAS No.: 108-46-3

EC No.: 203-585-2

If you have any needs or questions, please contact us at

Further Information

EU Notification Detail


We have launched a LinkedIn newsletter to keep you up to date on the latest developments across the chemical industry including food and FCMs and personal and home care.

Contact Us
+353 1 477 3710 (EU)
+44 20 3239 9430 (UK)
+1 703 520 1420 (USA)
+86 571 8720 6574 (CN)
+82 2 6347 8816 (KR)